Roth Comments on Regeneron's (REGN) MAA Submission for EYLEA to EU; Reaffirms 'Buy' Rating
Roth Capital reiterates its Buy rating and $382 target price on Regeneron Pharma (Nasdaq: REGN) after the company announced that it submitted a marketing authorization application with the EU for EYLEA.
Analyst Joseph Pantginis sees EYLEA getting approved in Europe for the BRVO indication based on positive, randomized phase III data.
Recall that a regulatory submission has also been made in the US for the drug for this indication. Recall that EYLEA was approved in the US in November 2011 for the treatment of wet AMD and in September 2012 for macular edema following CRVO. EYLEA is also approved in the EU for wet AMD and macular edema following CRVO. Regulatory submissions have also been made in both the US and EU for diabetic macular edema (DME). The PDUFA dates are August 18, 2014 for DME and October 23, 2014 for the BRVO indication. In 1Q14, recall that REGN noted that the lower-than-estimated sales of EYLEA in the U.S. were due to the severe weather during the winter, preventing a large population of patients from reaching their physicians. Additionally, a decrease in distributor inventory in the first quarter negatively impacted sales. REGN noted that inventory levels are back to normal at the distributor level and yearly guidance for EYLEA sales remains at $1.7-$1.8 billion. We believe the two upcoming PDUFA dates should drive EYELA growth.
Shares of Regeneron Pharma closed at $309.47 yesterday.
You May Also Be Interested In
- Roth Boosts PT on Regeneron (REGN) to $399 Following ODYSSEY Phase III Data, EYLEA Approval
- Akamai (AKAM) PT, Estimates Raised at Piper Jaffray on Strong Q2
- Goldman Sachs Downgrades Unilever (UN) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRoth Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!